Cerecin appoints two new members to its Scientific Advisory Board following announcement of new Singapore headquarters

Professor Chua Nam-Hai and Associate Professor Christopher Chen will provide scientific advisory support as Cerecin continues development of brain health and dementia solutions and expands into the Asian market

SINGAPORE,Oct. 16,2018 -- Brain health-focused pharmaceutical company Cerecin,today announced the appointment of two healthcare industry leaders to its Scientific Advisory Board (SAB). They are Associate Professor Christopher Chen from the Department of Pharmacology at the National University of Singapore's Yong Loo Lin School of Medicine (NUS Medicine),and Professor Chua Nam-Hai,Chief Scientific Advisor,Wilmar International Limited,Deputy Chairman,Temasek Life Sciences Laboratory and Distinguished Visiting Professor,Department of Biochemistry,NUS Medicine,and a Fellow of the UK Royal Society. They join continuing SAB members Dr. Jeff Cummings of the Cleveland Clinic,Dr. Martin Farlow of the University of Indiana,Dr. Michael Weiner of the University of California San Francisco,and Dr. Bruno Vellas of the Universite de Toulouse.

These appointments reaffirm Cerecin's commitment to growth in Asia and its confidence in its new home in Singapore. Both Associate Professor Chen and Professor Chua bring with them a great wealth of knowledge in the fields of neuroscience,biology and the Asian life science ecosystem.

Dr. Charles Stacey,President and CEO of Cerecin,commented: "We are excited to welcome Associate Professor Chen and Professor Chua to our Scientific Advisory Board composed of international thought leaders. We are confident that Cerecin will benefit immensely from Professor Chua's profound knowledge in biotechnology and the life science environment in Asia,as well as Associate Professor Chen's expertise in dementia and rich experience in conducting stroke and dementia clinical trials."

"I am honored to become part of Cerecin's Scientific Advisory Board. I am keenly interested in Cerecin's success,given Wilmar's recent investment in this neurology focused pharma company,and my long term commitment to scientific pursuits. I hope to help the two organizations realize the many synergies that present themselves," said Professor Chua.

"I am excited to be joining the Scientific Advisory Board of Cerecin given how important brain health will be for Asia and us here in Singapore. We are expecting the number of people suffering from dementia here in Singapore to more than double by 2030. Cerecin's product development work is of critical importance to us and I look forward to supporting their efforts," said Associate Professor Chen.

Both Professor Chua and Associate Professor Chen join the Scientific Advisory Board at a time when Cerecin looks to renew its commitment to drug development and increase its offering to the Asian market,cementing its leading position in pioneering novel therapeutic approaches to treat neurodegenerative disease globally.

About Cerecin

Cerecin,previously Accera,Inc.,is a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world. Cerecin is led by an expert executive management team with globally recognized specialists in central nervous system diseases and supported by two partners,Nestle Group and Wilmar Ventures Pte. Ltd. Cerecin's lead compound,tricaprilin,is intended to address the metabolic deficit that is known to be characteristic of Alzheimer's disease by providing the brain with an alternative energy substrate. Cerecin is currently preparing this newly reformulated compound for global pivotal studies. Bringing together the deep industry expertise of its leadership team and the extensive market access capabilities of its strategic investors,Cerecin is growing its global presence to build a brighter future for Alzheimer's patients.

For more information visit www.cerecin.com.

Professor Chua Nam-Hai

Professor Chua is Chief Scientific Advisor,Yong Loo Lin School of Medicine,National University of Singapore. Also a Fellow of the UK Royal Society,an Academician of Taiwan's Academia Sinica,and a Foreign Academician of the Chinese Academy of Sciences,China,Professor Chua has advised government organisations,institutions and MNCs worldwide,including Monsanto,DUPONT,Sumitomo Chemical Corporation,and biotechnology-related entities. He received his B.Sc. from University of Singapore; AM and Ph.D from Harvard University; and an honorary doctorate from Nanyang Technology University. He was awarded Public Administration Medal (Gold) by the Singapore Government in 2002.

About Associate Professor Christopher Chen

Associate Professor Christopher Chen studied pre-clinical medicine at Fitzwilliam College,Cambridge University,where he majored in Physiology & Psychology. His clinical training was at the University of Oxford where he where he was a Research Fellow jointly with the Institute of Neurology,London. He is currently a faculty member of the Department of Pharmacology at the National University of Singapore's Yong Loo Lin School of Medicine,and Director of the Memory Aging and Cognition Centre,National University Health System. Since returning to Singapore in 1995,Dr Chen has developed a comprehensive multi-disciplinary dementia programme and encouraged collaborative research in the Asia-Pacific region and beyond. His current focus is on developing a regional network for innovative trials into conditions prevalent and pertinent to Asia. His major research and clinical interests are in neurochemistry,molecular biology and treatment of stroke and dementia.

© 2018 Cerecin AC-18-836 10/18